摘要
新辅助化疗在治疗浸润肌层膀胱癌中的应用目前还存在争议。以顺铂为基础的联合新辅助化疗被考虑作为那些浸润肌层或局限晚期,但仍是可手术患者的一种标准治疗。那些不合适或拒绝做根治性膀胱切除术的患者,新辅助化疗联合或不联合放疗可使保留膀胱的患者获得很好的临床疗效。现主要综述局限晚期膀胱癌患者新辅助化疗的研究进展。
The use of neoadjuvant and adjuvant chemotherapy in the treatment of muscle-invasive bladder cancer is still controversial.The evidence currently available suggests that neoadjuvant cisplatin-based combination chemotherapy should be considered as the standard regimen for patients with muscle-invasive or locally advanced operable bladder cancer.In patients who are either unsuitable for or refuse radical cystectomy,neoadjuvant chemotherapy with or without radiation can render bladder preservation possible for patients who attain an excellent clinical response.This paper mainly reviews the research of neoadjuvant chemotherapy for patients with locally advanced bladder cancer.
出处
《医学综述》
2010年第11期1649-1651,共3页
Medical Recapitulate
关键词
膀胱癌
化疗
保留膀胱
Bladder cancer
Chemotherapy
Bladder preservation
